Victory Capital Management
GBIO

Victory Capital Management’s Generation Bio GBIO Stock Holding History

Victory Capital Management’s Portfolio GBIO Stock Details GBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,921
Closed -$102K – 2639
2022
Q3 		$102K Buy
1,921
+149
+8% +$9.32K ﹤0.01% 2476
2022
Q2 		$116K Sell
1,772
-2
-0.1% -$131 ﹤0.01% 2443
2022
Q1 		$112K Sell
1,774
-7,883
-82% -$457K ﹤0.01% 2499
2021
Q4 		$683K Sell
9,657
-117,698
-92% -$20.5M ﹤0.01% 2000
2021
Q3 		$31.9M Buy
127,355
+15,257
+14% +$3.65M 0.03% 708
2021
Q2 		$30.2M Buy
112,098
+3,817
+4% +$1.14M 0.03% 752
2021
Q1 		$30.8M Buy
108,281
+36,346
+51% +$11.6M 0.03% 744
2020
Q4 		$20.4M Sell
71,935
-14,765
-17% -$4.74M 0.02% 863
2020
Q3 		$26.8M Buy
86,700
+1,831
+2% +$438K 0.03% 670
2020
Q2 		$17.8M Buy
+84,869
New +$18.9M 0.02% 824

Other funds holding GBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Victory Capital Management's GBIO Position: Q4 2022 in Review

Victory Capital Management sold out of Generation Bio (GBIO) in Q4 2022, closing a stake of 1,921 shares — an estimated $102K sold.

Victory Capital Management first reported a position in GBIO in Q2 2020 and held it in 10 quarters. The position peaked at $31.9M in Q3 2021. 94 funds tracked by Wall St. Rank hold GBIO as of Q4 2022.

  • Victory Capital Management reported no remaining Generation Bio position as of Q4 2022 after selling out during the quarter.
  • Victory Capital Management sold 1,921 Generation Bio shares in Q4 2022, an estimated $102K.
  • Victory Capital Management first reported a position in Generation Bio in Q2 2020 and held it in 10 quarters.
  • Victory Capital Management's Generation Bio position peaked at $31.9M in Q3 2021.
  • 94 funds tracked by Wall St. Rank held Generation Bio as of Q4 2022.

Based on Victory Capital Management's 13F filing for Q4 2022, filed 9 Feb 2023.